Mutational analysis of PRKAR1A and Gs(alpha) in sporadic adrenocortical tumors

R Libé1, G Mantovani, S Bondioni

  • 1Institute of Endocrine Sciences, University of Milan, Ospedale Maggiore IRCCS, Milan, Italy.

Insights

Genetic mutations in the cAMP pathway, including PRKAR1A and gsp oncogene, are rare in adrenocortical tumors causing Cushing syndrome. This study found no PRKAR1A mutations and only one gsp mutation in tested samples.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Adrenocortical tumor pathogenesis is poorly understood.
  • The cAMP pathway, activated by ACTH, is implicated in some functioning tumors.
  • PRKAR1A mutations and gsp oncogene mutations are known alterations in specific adrenocortical conditions.

Purpose of the Study:

  • To investigate PRKAR1A mutations and loss of heterozygosity (LOH) in ACTH-independent Cushing syndrome.
  • To screen for gsp oncogene mutations in non-PPNAD adrenocortical adenomas.
  • To determine the frequency of these specific genetic alterations in this tumor cohort.

Main Methods:

  • PCR and direct sequencing to analyze the PRKAR1A coding sequence.
  • Evaluation of heterozygosity for polymorphisms to assess LOH at the PRKAR1A locus.
  • Genetic analysis of 10 ACTH-independent adrenocortical adenomas.

Main Results:

  • No mutations were detected in the PRKAR1A gene across the analyzed tumors.
  • Heterozygosity for polymorphisms indicated the absence of LOH in most samples.
  • A single case of gsp mutation was identified in one adenoma.

Conclusions:

  • PRKAR1A mutations are not a significant factor in this cohort of ACTH-independent Cushing syndrome.
  • Gsp oncogene mutations are also infrequent in non-PPNAD adrenocortical adenomas.
  • The identified genetic alterations activating the cAMP pathway are rare in adrenocortical tumors.